BiotechTube
Home/Quince Therapeutics/Brendan Hannah, M.B.A.
BH

Brendan Hannah, M.B.A.

Chief Operating Officer and Chief Business Officer

Quince Therapeutics

Therapeutic Areas

Rare DiseasesNeurodegenerativeInflammatory

Quince Therapeutics Pipeline

DrugIndicationPhase
eDSP (EryDex)Ataxia-Telangiectasia (A-T)Phase 3

Leadership Team at Quince Therapeutics

DT
Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, and Board Member
CR
Charles Ryan, J.D., Ph.D.
President
GM
Giovanni Mambrini, MSc
Chief Technology Officer
DL
David Lamond
Board of Directors, President of En Pointe, LLC
CS
Christopher Senner
Board of Directors, Chief Financial Officer of Exelixis
View full Quince Therapeutics profile